Inflammation from sterile dialysis solutions and the longevity of the peritoneal barrier

Clinical Nephrology

Volumn 68, Issue 6, 2007, Pages 341-348

  Flessner, M F ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Biocompatibility; Cytokine peritoneum; Inflammation; Peritoneal dialysis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; ANGIOTENSINOGEN; BASIC FIBROBLAST GROWTH FACTOR; C REACTIVE PROTEIN; CA 125 ANTIGEN; CD31 ANTIGEN; CREATININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRINOGEN; FIBRONECTIN; GLUCOSE; GLUCOSE DEGRADATION PRODUCT; GLUCOSE TRANSPORTER; HYALURONIC ACID; ICODEXTRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PERITONEAL DIALYSIS FLUID; PEROXIDE; PROSTAGLANDIN; PROTEIN KINASE C; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

BACTERIUM CULTURE; BIOCOMPATIBILITY; BIOFILM; CELLULAR IMMUNITY; CHRONIC KIDNEY DISEASE; CREATININE CLEARANCE; CYTOKINE RELEASE; DIALYSIS MEMBRANE; FOREIGN BODY REACTION; HEMODIALYSIS; HEREDITY; HISTOPATHOLOGY; HUMAN; MACROPHAGE; MESOTHELIUM CELL; NONHUMAN; PATHOGENESIS; PERITONEAL BIOPSY; PERITONEAL CATHETER; PERITONEAL DIALYSIS; PERITONITIS; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ULTRAFILTRATION; UREMIA;

EID: 37149032116     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp68341     Document Type: Review

References (45)

1. Agalou S, Ahmed N, Babaei-Jadidi R, Dawnay A, Thornalley PJ. Profound mishandling of protein glycation degradation products in uremia and dialysis. J Am Soc Nephrol. 2005; 16: 1471-1485.
2. Boulanger E, Moranne O, Wautier M-P, Witko-Sarsat V, Descamps-Latscha B, Kandoussi A, Grossin N, Wautier J-L. Changes in glycation and oxidation markers in patients starting peritoneal dialysis: a pilot study. Perit Dial Int. 2006; 26: 207-212.
3. Brulez HFG, Verbrugh HA. First-line defense mechanisms in the peritoneal cavity during peritoneal dialysis. Perit Dial Int. 1995; 15 (Suppl 7): S24-S34.
4. Chung SH, Heimburger O, Stenvinkel P, Wang T, Lindholm B. Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent peritoneal dialysis patients. Perit Dial Int. 2003; 23: 174-183.
5. Combet S, Miyata T, Moulin P, Pouthier D, Goffin E, Devuyst O. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis. J Am Soc Nephrol. 2000; 11: 717-728.
6. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999; 284: 1318-1322.
7. Credit K, Henderson K, Varpelt H, He Z, Flessner MF. Use of indwelling catheter in a chronic peritoneal exposure model markedly increases inflammatory changes (Abstract). J Am Soc Nephrol. 2006; 17: 750A.
8. Dasgupta MK, Ulan RA, Betteher K, Burns V, Costerton JW. Effect of exit site infection and peritonitis on the distribution of biofilm encased adherent bacterial microcolonies (BABM) on Tenckhoff (T) catheters in patients undergoing continuous ambulatory peritoneal dialysis. Adv Perit Dial. 1986; 2: 102-109.
9. Dasgupta MK, BettcherK, Ulan RA, Costerton JW. Relationship of adherent bacterial biofilms to peritonitis in chronic ambulatory peritoneal dialysis. Perit Dial Bull. 1987; 7: 168-173.
10. Dasgupta MK, Costerton JW. Significance of biofilm-adherent bacterial microcolonies on Tenckhoff catheters of CAPD patients. Blood Purif. 1989; 7: 144-155.
11. Dasgupta MK. Biofilms in peritoneal dialysis. Perit Dial Int. 2001; 21(Suppl 3): S213-S217.
12. Dasgupta MK. Biofilms and infection in dialysis patients. Semin Dial. 2003; 15: 338-346.
13. Davies SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant. 1996; 11: 498-506.
14. Davies SJ, Phillips L, Naish PF, Russell GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal transport. J Am Soc Nephrol. 2001; 12: 1046-1051.
15. Davies SJ, Brown EA, Frandsen NE, Rodrigues AS, Rodriguez-Carmona A, Vychytil A, MacNamara E, Ekstrand A, Tranaeus A, Filho JCD. Longitudinal membrane function in functionally anuric patients treated with APD: Data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int. 2005; 67: 1609-1615.
16. Dobbie JW, Anderson JD, Hind C. Long-term effects of peritoneal dialysis on peritoneal morphology. Perit Dial Int. 1994; 14 (Suppl 3): S16-S20.
17. Finkelstein ES, Jekel J, Troidle L, Gorban-Brennan N, Finkelstein FO, Bia FJ. Patterns of infection in patients maintained on long-term peritoneal dialysis therapy with multiple episodes of peritonitis. Am J Kidney Dis. 2002; 39: 1278-1286.
18. Flessner MF, Henegar J, Bigler S, Genous L. Is the peritoneum a significant transport barrier in peritoneal dialysis? Perit Dial Int. 2003; 23: 542-549.
19. Flessner MF Credit K, Henderson K, Vanpelt H, Potter R, He Z, Henegar J Robert B. Effect of catheter on time course of structural and transport changes in the peritoneum exposed to sterile solutions. J Am Soc Nephrol. 2007; 18: 2294-2502.
20. Flessner MF. Transport of Water-Soluble Solutes Between the Peritoneal Cavity and Plasma in the Rat. Ann Arbor, MI: University of Michigan; 1981. p. 346.
21. Flessner MF. Peritoneal transport physiology: insights from basic research. J Am Soc Nephrol. 1991; 2: 122-135.
22. Flessner MF. The transport barrier in intraperitoneal therapy. Am J Physiol. 2005; 288: F433-F442.
23. Flessner MF. Intraperitoneal drug therapy: physical and biological principles. In: Beelen RH: Multidisciplinary Management of Peritoneal Carcinomatosis. New York, Springer; 2006a. p. 131-152.
24. Flessner MF. Sterile solutions and peritoneal inflammation. Contrib Nephrol. 2006b; 150: 156-165.
25. Gillerot G, Goffin E, Michel C, Evenepoel P, Van Biesen W, Tintillier M, Stenvinkel P, Heimburger O, Lindholm B, Nordfors L, Robert A, Devuyst O. Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. Kidney Int, 2005; 67: 2477-2487.
26. Gorman S, Adair C, Mawhinney W. Incidence and nature of peritoneal catheter biofilm determined by electron and confocal laser scanning microscopy. Epidemiology and Infection. 1994; 112: 551-559.
27. Heimburger O, Waniewski J, Werynski A. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int. 1990; 38: 495-506.
28. Jones S, Holmes C, Krediet RT, Mackenzie RK, Faict D, Tranaeus A, Williams JD, Coles GA, Topley N. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int. 2001; 59: 1529-1538.
29. Kiernan L, Finkelstein FO, Kliger AS, Gorban-Brennan N, Juergensen P, Mooraki A, Brown E. Outcome of polymicrobial peritonitis in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis. 1995; 25: 461-464.
30. Krediet RT, Lindholm B, Rippe B. Pathophysiology of peritoneal membrane failure. Perit Dial Int. 2000; 20 (Suppl 4): S22-S42.
31. Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, Kim YH, Kim YL, Kim DJ, Kim YS, Alin C, Kim MJ, Shin SK. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (balance). Perit Dial Int. 2005; 25: 248-255.
32. Miyata T, Devuyst O, Kurokawa K, van Ypersele de Strihou Y. Toward better dialysis compatibility: advances in the biochemistry and pathophysiology of the peritoneal membranes. Kidney Int. 2002; 61: 375-386.
33. Mortier S, Faict D, Lameire NH, de Priese AS. Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model. Kidney Int. 2005; 67: 1559-1565.
34. Musi B, Braide M, Carlsson O, Wieslander A, Albrektsson A, Ketteler M, Westenfeld R, Floege J, Rippe B. Biocompatibility of peritoneal dialysis fluids: long-term exposure of nonuremic rats. Perit Dial Int. 2004; 24: 37-47.
35. Pecoits-Filho R, Carvalho M, Stenvinkel P, Lindholm B, Heimburger O. Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int. 2006; 26: 53-63.
36. Read RR, Eberwein P, Dasgupta MK, Grant SK, Lam K, Nickel JC, Costerton JW. Peritonitis in peritoneal dialysis: bacterial colonization by biofilm spread along the catheter surface. Kidney Int. 1989; 35: 614-621.
37. Shostak A, Pivnik E, Gotloib L. Cultured rat mesothelial cells generate hydrogen peroxide: a new player in peritoneal defense? J Am Soc Nephrol. 1996; 7: 2371-2378.
38. Swartz R, Messana J, Holmes C, Williams J. Biofilm formation on peritoneal catheters does not require the presence of infection. Trans Am Soc Artif Intem Organs. 1991; 37: 626-634.
39. Topley N. The cytokine network controlling peritoneal inflammation. Perit Dial Int. 1995; 5 (Suppl 7): S35-S46.
40. Verger C, Chesneau A, Thibault M, Batalie N. Biofilm on the Tenckhoff catheters: a negligible source of contamination. Perit Dial Bull. 1987; 7: 178-184.
41. Ward KH, Olson ME, Lam K, Costerton JW. Mechanism of persistent infection associated with peritoneal implants. J Med Microbiol. 1992; 36: 406-413.
42. Williams JD, Craig KJ, Topley N, Ruhland CV, Fallon M, Newman GR, Mackenzie RK, Williams GT. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol. 2002; 13: 470-479.
43. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, Passlick-Deetien J. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int. 2004; 66: 408-418.
44. Witowski J, Jorres A. Preventing peritoneal fibrosis - an ace up our sleeve? Perit Dial Int. 2005; 25: 25-29.
45. Yanez-Mo M, Lara-Pezzi E, Selgas R, Ramierez-Huesca M, Dominguez-Jimenez C, Jimienez-Herrernan JA, et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med. 2003; 348: 403-413.